Actinogen Medical Limited (ASX: ACW) announces that a recent trial designed to confirm therapeutic blood levels of the ...

The European Commission has approved a new film-coated tablet formulation of Sino-American oncology-focused biotech BeOne Medicines’ Brukinsa (zanubrutinib) for all approved indications.

Actinogen Medical ( ($AU:ACW) ) has shared an update. Actinogen Medical announced successful trial results for their Xanamem tablet formulation, ...

BeOne Medicines recently announced that the European Commission approved a new film-coated tablet formulation of BRUKINSA (zanubrutinib) for all existing indications, halving the required daily pill ...

The new tablet formulation maintains BRUKINSA’s dosing flexibility by providing patients and prescribers with the option of once- or twice-daily dosing and is designed to simplify management of ...

BeOne Medicines (ONC) announced that the European Commission has approved a new film-coated tablet formulation of Brukinsa – zanubrutinib – for ...

Chewable tablets have also found application in veterinary medicines. This paper reviews considerations for the formulation of chewable tablets including sensory characteristics, chewability ...

Venlafaxine HCl extended-release is a serotonin-norepinephrine reuptake inhibitor available in capsule and tablet formulations. The capsule is marketed under the brand name Effexor XR® and is ...

The FDA has approved a twice-a-day formulation of Ferriprox® (deferiprone; Chiesi) for the treatment of transfusional iron overload due to thalassemia syndromes when current chelation therapy is ...

BeOne Medicines Ltd., a global oncology company, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending ...